Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DHA:IBNSINA's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.6 * Ranked among companies with meaningful Equity-to-Asset only.
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
The IBN SINA Pharmaceutical Industry Equity-to-Asset Related Terms
The IBN SINA Pharmaceutical Industry Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The IBN SINA Pharmaceutical Industry Equity-to-Asset Chart
The IBN SINA Pharmaceutical Industry Annual Data
Trend
Equity-to-Asset
The IBN SINA Pharmaceutical Industry Semi-Annual Data
Equity-to-Asset
DHA:IBNSINA vs IMNPQ: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, The IBN SINA Pharmaceutical Industry's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The IBN SINA Pharmaceutical Industry Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The IBN SINA Pharmaceutical Industry's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where The IBN SINA Pharmaceutical Industry's Equity-to-Asset falls into.
The IBN SINA Pharmaceutical Industry Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a Equity-to-Asset of 0.00 as of . 20. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. According to the industry distribution chart, The IBN SINA Pharmaceutical Industry ranks #999999 out of 1008 companies in the Drug Manufacturers industry.
Is The IBN SINA Pharmaceutical Industry's Equity-to-Asset too high?
The IBN SINA Pharmaceutical Industry's current Equity-to-Asset is 0.00. Based on the distribution chart, The IBN SINA Pharmaceutical Industry ranks #999999 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, The IBN SINA Pharmaceutical Industry has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does The IBN SINA Pharmaceutical Industry's Equity-to-Asset compare to IMNPQ?
According to the Drug Manufacturers industry distribution chart, The IBN SINA Pharmaceutical Industry ranks #999999 out of 1008 companies for Equity-to-Asset. This places The IBN SINA Pharmaceutical Industry in the lower half of its industry. The industry median Equity-to-Asset is 0.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The IBN SINA Pharmaceutical Industry's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The IBN SINA Pharmaceutical Industry stock overvalued right now?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a current Equity-to-Asset of 0.00. The current Equity-to-Asset is 0.00. The IBN SINA Pharmaceutical Industry's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For The IBN SINA Pharmaceutical Industry (DHA:IBNSINA), the current Equity-to-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The IBN SINA Pharmaceutical Industry PLC is engaged in the production and marketing of pharmaceutical drugs and natural medicines in both the local and international market.
20GF Score
Get the complete analysis for DHA:IBNSINA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:IBNSINA has been successfully added to your 
